Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Retained Earnings: 2020-2024

Historic Retained Earnings for Tango Therapeutics (TNGX) over the last 5 years, with Dec 2024 value amounting to -$501.6 million.

  • Tango Therapeutics' Retained Earnings fell 21.67% to -$564.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$564.4 million, marking a year-over-year decrease of 21.67%. This contributed to the annual value of -$501.6 million for FY2024, which is 35.10% down from last year.
  • Latest data reveals that Tango Therapeutics reported Retained Earnings of -$501.6 million as of FY2024, which was down 35.10% from -$371.3 million recorded in FY2023.
  • Tango Therapeutics' Retained Earnings' 5-year high stood at -$103.1 million during FY2020, with a 5-year trough of -$501.6 million in FY2024.
  • Over the past 3 years, Tango Therapeutics' median Retained Earnings value was -$371.3 million (recorded in 2023), while the average stood at -$380.8 million.
  • Data for Tango Therapeutics' Retained Earnings shows a maximum YoY crashed of 67.05% (in 2022) over the last 5 years.
  • Over the past 5 years, Tango Therapeutics' Retained Earnings (Yearly) stood at -$103.1 million in 2020, then tumbled by 56.48% to -$161.3 million in 2021, then crashed by 67.05% to -$269.5 million in 2022, then crashed by 37.75% to -$371.3 million in 2023, then crashed by 35.10% to -$501.6 million in 2024.